Z.M.D Diagnostics is developing an automated diagnosis system to measure the oncolytic activity of bacteria in the intestinal microflora. The system is designed to detect cancer long before a tumor appears by measuring the strength of certain bacteria in the gut. The Z.M.D system can also predict the recurrence of cancer in patients in remission by measuring the strength of the patients immune system. The system is capable of diagnosing the presence of cancer, though it cannot determine the location of the tumor. The patent-protected system comes in two designs, one for hospital use and one for home use. Z.M.Ds intestinal microflora bacteria are developed in the companys laboratory and tested through the stages of validation and clinical studies. The preliminary results have been highly encouraging and suggest a significant clinical future. The company operates under the Z.M.D Group and is a sister company of Z.M.D Medical, a spin-off of Sheba Medical Center-Tel Hashomer.
Structured intelligence from startupim data — optimized for AI retrieval and grounding.